Skip to content

Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière

Cohorte de Maladies Neurovasculaires Prises en Charge à la Phase aiguë et Suivies à Lariboisière

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06026696
Acronym
NERVAL
Enrollment
5000
Registered
2023-09-07
Start date
2023-09-30
Completion date
2038-09-30
Last updated
2023-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhagic Stroke, Ischemic Stroke

Brief summary

Neurovascular diseases can cause ischaemic or haemorrhagic strokes. While the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. What's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. Patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the Lariboisière neurovascular intensive care unit (USINV) could provide a particularly rich resource.

Interventions

OTHERfollow-up

Long term follow-up

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Adult patients ≥18 years 2. Patients admitted to the Neurovascular Intensive Care Unit with acute cerebrovascular disease OR Patients managed for acute cerebrovascular pathology with or without stroke by the Lariboisière neurology team. 3. No opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative.

Exclusion criteria

1. Patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship 2. Patient suffering from a rare neurovascular disease and being followed at the Centre de référence des maladies vasculaires rares du cerveau et de l'oeil (CERVCO)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of a vascular eventUp to 5 yearsVascular event is defined as : myocardial infarction, ischaemic or haemorrhagic stroke, recurrence of cerebrovascular disease, systemic embolism, congestive heart disease, vascular or non-vascular death during patient follow-up.

Secondary

MeasureTime frameDescription
Treatment adherenceUp to 10 years
Incidence of headachesUp to 10 years
Incidence of deathUp to 10 yearsAge and causes of death
Prevalence of vascular risk factorsUp to 10 yearsMedical history, LDL (Low Density Lipoprotein), Tobacco, Arterial pressure, HbA1C (glycated hemoglobin)
Number of adverse eventsUp to 10 yearsEvaluation of treatment tolerance
Incidence of a vascular eventUp to 10 yearsVascular event is defined as : myocardial infarction, ischaemic or haemorrhagic stroke, recurrence of cerebrovascular disease, systemic embolism, congestive heart disease, vascular or non-vascular death during patient follow-up.
Modified Rankin scoreAt 3 monthsThe modified Rankin score is a 6 point disability scale varying between 0 to 5. The higher the score, the greater the disability.
Occurrence of intercurrent pathologies requiring specific treatmentUp to 10 yearsPathologies are defined as : anxiety-depressive disorder, dementia, comititude, neoplasia, venous thromboembolism, haemorrhage, systemic disease, respiratory insufficiency
Obstetrical prognosisUp to 10 yearsIncidence of pregnancies, complications, delivery methods
Number of associated treatmentsUp to 10 yearsDescription of the types of treatment used

Contacts

Primary ContactPeggy Reiner, Dr
peggy.reiner@aphp.fr+33149956525
Backup ContactJérôme Lambert, Dr
jerome.lambert@u-paris.fr+33142499742

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026